Openfederal fundingFederal coverageTier 1 intelligence

A grant from DOD-AMRAA

DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant

DOD-AMRAA offers this federal opportunity for work related to Science and Technology and other Research and Development, Health, Community Development. Organizations serving National should verify the requirements below before committing proposal time.

Start here · Eligibility

Check whether your organization qualifies

Answer 5 focused questions in about 60 seconds before investing time in the application.

Take Eligibility Quiz
1 source-confirmed criterion · No signupReview criteria

Potential award

Not specified

Time remaining

38 days

Application load

Moderate effort

Best next move

Take the eligibility quiz

Apply

Verified against the source on 8/21/2026

01

Start here

Confirm eligibility

Check your fit in about 60 seconds.

Eligibility requirementsQuestion 1 of 5
About 60 seconds totalInferred criterion

Does your proposed work directly align with Science and Technology and other Research and Development, Health, Community Development, Food Security, Research?

What does this mean?

Science and Technology and other Research and Development, Health, Community Development, Food Security, Research

Review supporting source ↗
Does your proposed work directly align with Science and Technology and other Research and Development, Health, Community Development, Food Security, Research?
Select an answer to continue

No signup · Answers stay in this browser session

This is an explainable self-assessment, not a win probability or legal determination. Hard eligibility conflicts are never averaged against softer program-fit signals. Always verify the official notice.

Optional Review source criteria and citations

Nonprofit status

Confirm nonprofit eligibility in the full notice.

Review source ↗
unclear

Geography

Nationwide availability is inferred from the catalog record; confirm the official notice.

Review source ↗
inferred

Organization size

No organization-size limit was captured.

Review source ↗
unclear

Program area

Science and Technology and other Research and Development, Health, Community Development, Food Security, Research

Review source ↗
inferred

Population served

No specific population was captured.

Review source ↗
unclear

Matching funds

No cost share is indicated.

Review source ↗
confirmed

Registrations

SAM.gov and Grants.gov registration may be required; confirm in the notice.

Review source ↗
inferred

Exclusions

Review the full notice for exclusions and prohibited uses.

Review source ↗
unclear
02

Grant-writer assessment

Understand the opportunity

Start with the practical interpretation. Open the complete source narrative when you need the underlying detail.

Plain-English explanation

Plain-English explanation

DOD-AMRAA offers this federal opportunity for work related to Science and Technology and other Research and Development, Health, Community Development. Organizations serving National should verify the requirements below before committing proposal time.

Not yet confirmed

What the funder is trying to accomplish

A specific statement of funder intent has not yet been editorially reviewed. Use the official description and program priorities as the controlling source.

Plain-English explanation

Strong-fit project signals

Projects should demonstrate a direct, substantive connection to Science and Technology and other Research and Development, Health, Community Development. This is directional guidance, not an eligibility determination.

Not yet confirmed

What reviewers may prioritize

Review criteria have not yet been captured. Do not assume general best practices replace the scoring criteria in the official notice.

Source dossier Read the full official program description
Source-backed synopsis

What this grant funds

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.

Applications must address one of the following focus areas:

· Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.

· Clinical Care: Improving aspects of clinical care and symptom management for ALS.

Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.

Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.

All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.

Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.

Read the complete official description ↗
03

Decision economics

Size the opportunity

Use the source facts below to judge whether the likely return justifies the application effort.

Award range
Not specified
Total program funding
$5,600,000
Expected awards
2
Geography
National
Cost share
Not indicated
Assistance listing
Not specified

Mission alignment

Compare your program with Science and Technology and other Research and Development, Health, Community Development.

Geographic fit

National

04

Working plan

Build the application

The generated milestones are planning aids. Only the official notice establishes required dates.

Requirements captured

Submission system
Grants.gov
Attachments
FY26 ALSRP PCTA Program Announcement
Contact
Jamie Shortall Grant Officer · help@eBRAP.org · 301-619-2393

Official deadline

September 30, 2026

Moderate effort based on requirements currently captured.

  1. Confirm eligibility, registrations, partners, and internal approval.

  2. Finalize project design, outcomes, and supporting evidence.

  3. Draft the narrative and detailed budget.

  4. Complete compliance review and collect attachments.

  5. Submit early and preserve the confirmation receipt.

05Past behaviorCompare historical awardsHistorical patterns provide context, but do not predict or guarantee future funding decisions.
No licensed historical awards are currently linked to this opportunity.
06Audit trailVerify the evidenceSee where the facts came from, when they were checked, and what has materially changed.

Source record

Source verified means the official record was successfully checked. It does not mean every eligibility or application field has been extracted.

Verification
verified
Source
grants gov
Last checked
8/21/2026, 9:01:22 AM
Content updated
8/10/2026, 10:25:57 PM
Review
Automated normalization; not yet expert-reviewed
Open official source ↗

Material changes

  1. Updated categories.

Verify before applying. Official funder documents control. Derived analysis and preparation dates should not replace the notice.
Keep searchingSimilar and alternative grantsExplore verified opportunities related by program area, funder, or funding type.
Quick answersFrequently asked questionsGet concise answers about DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant.
Is DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant currently open?

Yes, based on the latest source record. The deadline is September 30, 2026, with 38 days remaining. Because funders can amend or extend notices, confirm the date and submission instructions on the official application page. The source was last checked 8/21/2026.

How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant provide?

DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant lists Not specified per award. The total program funding recorded is $5,600,000. DOD-AMRAA expects to make approximately 2 awards, although the final number may vary.

Who can apply to DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant?

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Applicants should still complete the eligibility quiz and verify every condition in the official notice; a general fit does not override exclusions or registration requirements.

Does DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant require matching funds?

No cost-share requirement is indicated in the captured source facts. Applicants should still verify the official budget instructions in case an amendment, program track, or specific cost category carries additional conditions.

What should I prepare before applying to DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award Grant?

Moderate effort is expected. The captured requirements include submission system, attachments, contact. Start by confirming eligibility and registrations, then work backward from September 30, 2026 using the preparation plan above.

Maevena

Grant intelligence for non-profits

Find current opportunities, understand the source evidence, and reach the authoritative next step with fewer surprises.

Trust the source

Maevena supports research and initial decisions. Always confirm final eligibility, deadlines, and application requirements with the official funder.

Report a correction
© 2026 Maevena. Evidence-backed grant intelligence for non-profits.